Table 5 Clinical studies of belinostat (PXD101)

I

Advanced hematological neoplasms(16)

Day 1 to 5 of a 21-day cycle

1000 mg/m²/d

[128]

I

AZA

Advanced myeloid neoplasms(230

Days 1-5 of a 28 day cycle

1000 mg/m²

[129]

I

Advanced refractory solid tumors(46)

Days 1-5 of a 21 day cycle

1000 mg/m²

SD 39%

[127]

II

relapsed malignant pleural mesothelioma(13)

Days 1-5 of a 21 day cycle

Belinostat is not active as monotherapy against recurrent malignant pleural mesothelioma

[122]

II

Platinum resistant epithelial ovarian tumors(EOC,18) and micropapillary/borderline ovarian tumors(LMP,12)

Days 1-5 of a 21 day cycle with 1000 mg/m2

EOC: SD 50%, PD25% N/E 25%; LMP: SD 75%, PR8.3%, N/E 16.6%

[130]